Company initiates development of CLBS119 for the repair of COVID-19 induced lung damage and expands its proprietary CD34+ cell therapy portfolio
Adds ~$16 million in funding bringing current cash to ~$34 million
Conference call begins today at 4:30 p.m. Eastern time
BASKING RIDGE, N.J. , May 07, 2020 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, provides a corporate update and announces financial results for the three months ended March 31, 2020.
Product Development and Financing Highlights
Caladrius initiates development of CLBS119, a CD34+ cell therapy specifically intended to repair COVID-19 induced lung damage
For thousands of COVID-19 survivors leaving hospitals around the world, vestiges of the virus will return home with them in the form of debilitating lung damage. Many companies are searching for treatments for the acute effects of the virus or for a vaccine that thwarts infection altogether. Caladrius, however, has taken a leadership position in helping those patients who have beaten the virus but have suffered potentially permanent lung damage in the battle. Initial evidence indicates that a large portion of the survivors of COVID-19 who required ventilatory support will suffer long-term, debilitating lung damage.1 Scientists learned in the aftermath of the first SARS epidemic that the coronavirus targets cells that express CD34.2 Depletion of that cell population generally is thought to be connected to the lung’s inability to repair itself.2 Early reports from the COVID-19 pandemic indicate that the endothelial cells that line the microvasculature of the lung are targeted by the virus and that the destruction of the lung microcirculation may be a critical factor in the inability of the lung to repair itself even after the virus has been eliminated.3 Clinical trials and preclinical models have shown that CD34+ cells act in a restorative and regenerative capacity in multiple organs, including models of severe lung inflammation.4 Research has also shown that a deficiency in vascular CD34+ cells can result in a predisposition to injury in the lungs.5 Caladrius has opened an Investigational New Drug (“IND”) application, agreed with the Food and Drug Administration (“FDA”) on a protocol and has begun manufacturing preparation with the intention of initiating a clinical trial as soon as possible to evaluate CLBS119 as a treatment to restore lung function specifically in patients who experienced severe SARS-CoV-2 infection and required ventilatory support due to respiratory failure.
CLBS12 development in Japan continues to yield promising results
The Company’s open-label, registration-eligible study of CLBS12, its SAKIGAKE-designated product candidate, in Japan for the treatment of critical limb ischemia (“CLI”), a disease with no currently available approved therapy6 and a higher mortality rate than all cancers except that of lung cancer,7 has shown positive results to date. The Buerger’s Disease cohort has concluded with 4 out of 7 (57%) patients achieving a positive outcome. Although the study enrollment, which had been targeted for completion this year, has been slowed by the impact of the COVID-19 pandemic in Japan, the Company is encouraged by the patient pre-screening pipeline that has been identified and hopes to conclude the trial enrollment rapidly once the coronavirus abates and physicians are again able to treat non-COVID-19 patients. Based on the data from the concluded Buerger’s Disease cohort and the data to date in the no-option CLI cohort, the Company affirms its expectation of the study’s ultimate success.
CLBS16 demonstrates ability to improve coronary flow reserve in patients and potentially reverse coronary microvascular dysfunction
Caladrius reported that it has concluded its ESCaPE-CMD study of CLBS16 for the treatment of coronary microvascular dysfunction (“CMD”), a disease that potentially afflicts millions annually with no current treatment options. The full data from that study will be presented at the SCAI 2020 Scientific Sessions Virtual Conference on May 14th and is expected to corroborate the positive partial results presented at the American Heart Association Scientific Sessions in November 2019. The Company is already taking steps necessary to initiate the next trial in CLBS16 development, a Phase 2b study, in the fall of 2020.
CLBS14 remains poised to enter a single confirmatory phase 3 clinical trial pending finalization of funding
The Company’s Phase 3 protocol for its RMAT-designated product candidate, CLBS14, for the treatment of no-option refractory angina (“NORDA”) remains ready to initiate pending sufficient funding to run the program to completion. Based on substantial data from previous Phase 1, 2, and 3 studies, Caladrius remains confident in the potential for clinical success once the program is executed.
An additional ~$16 million of capital (~$11 million of which is non-dilutive) added to balance sheet
Notwithstanding the challenging financial macro-environment, Caladrius recently announced that it secured approximately $10.9 million of non-dilutive capital from the sale of its New Jersey net operating losses (“NJ NOLs”) through the New Jersey Technology Business Tax Certificate Transfer Program. Soon thereafter it raised an additional $5.0 million pursuant to a registered direct institutional offering priced at-the-market under Nasdaq rules. This infusion of capital at this time once again demonstrates the Company’s ability to acquire non-dilutive capital. The successful completion of the registered direct offering during the COVID-19 pandemic also reinforces the attractiveness of the Company, its progress and the potential of its programs to the capital markets. The collected funds will, among other things, support the continued advancement of its ongoing CD34+ technology-based clinical programs.
“Throughout this extraordinary time, we remain steadfast in our commitment to advance our CD34+ cell technology-based clinical development programs, even as the global COVID-19 pandemic provokes unprecedented challenges for product development,” stated David J. Mazzo, Ph.D., President and Chief Executive Officer of Caladrius. “In fact, we have rallied to address the challenges of the pandemic and responded by defining and quickly moving to development CLBS119. We’ve done this while further securing our financial situation at a time when other companies are being forced to take draconian measures just to survive financially.
“Despite the global uncertainty brought about by the coronavirus, we are excited about what lies ahead in 2020 and expect to build on the momentum we generated during the first quarter,” concluded Dr. Mazzo.
First Quarter 2020 Financial Highlights
Research and development expenses for the first quarter of 2020 were $1.5 million, a 26% decrease compared with $2.0 million for the first quarter of 2019. Research and development in both periods focused on the advancement of our ischemic repair platform. More specifically, R&D expense was incurred as a result of our ongoing registration-eligible study for CLBS12 in critical limb ischemia in Japan, along with the concluding expenses for our ESCaPE-CMD clinical study for CLBS16 in coronary microvascular dysfunction. Note that the majority of costs associated with the ESCaPE-CMD clinical trial were covered by a grant from the National Institutes of Health.
General and administrative expenses, which focus on general corporate related activities, remain constant and were approximately $2.6 million for both the first quarters of 2020 and 2019.
The net loss for the first quarter of 2020 was $4.0 million, or $0.38 per share, compared with $4.4 million, or $0.44 per share, for the first quarter of 2019.
Balance Sheet Highlights
As of March 31, 2020, Caladrius had cash and cash equivalents of $20.7 million. Together with the combined net proceeds from the sale of the NJ NOLs and the registered direct offering in April 2020, our cash and cash equivalents today are approximately $34 million. Based on existing programs and projections, the Company remains confident that its current cash balances will fund its operations into the second half of 2021.
Conference Call
Caladrius management will host a conference call for investors beginning at 4:30 p.m. ET on Thursday, May 7, 2020 to discuss the financial results, provide a business update and answer questions.
Shareholders and other interested parties may participate in the conference call by dialing 866-595-8403 (domestic) or 706-758-9979 (international) and referencing conference ID number 8869677. The conference call will also be webcast live under the Investors section of the Company’s website at www.caladrius.com.
For those unable to participate in the live conference call, a replay will be accessible approximately two hours after its completion through May 14, 2020, by dialing 855-859-2056 (domestic) or 404-537-3406 (international) and referencing conference ID number 8869677. A webcast of the call will also be archived for 90 days under the Investors section of the Company’s website at www.caladrius.com.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, cardiovascular disease. We are developing a first- in-class cell therapy product that is based on the notion that our body contains finely tuned mechanisms for self-repair. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.
The Company’s current product candidates include CLBS119, a CD34+ cell therapy product candidate for the repair of lung damage found in patients with severe COVID-19 infection who experienced respiratory failure, for which the Company plans to initiate a clinical trial in the coming months as well as three developmental treatments for ischemic diseases based on its CD34+ cell therapy platform: CLBS12, recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; CLBS16, the subject of a recently completed positive Phase 2 clinical trial in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); and CLBS14, a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”). For more information on the company, please visit www.caladrius.com.
1Yuhui Wang, et al, Radiology, March 19, 2020
2Chen Y, Chan VS, Zheng B, et al. A novel subset of putative stem/progenitor CD34+Oct-4+ cells is the major target for SARS coronavirus in human lung. J Exp Med. 2007;204(11):2529‐2536. doi:10.1084/jem.20070462
3Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417‐1418. doi:10.1016/S0140-6736(20)30937-5
4Abd-Allah, et al, Cytotherapy, 2015;17(4):443-53
5Lo, Gold, Scheer, et al.: CD34 Maintains Lung Vascular Integrity after Injury
6Cacione DG, et al, Pharm. treatment of Buerger’s Disease, Cochrane Database of Systematic Reviews, 2016, (3) CD011033
7Mustapha, J. A., Katzen, B. T., et al. (2019, May). Endovascular Today, 18(5), 80-82
Safe Harbor for Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. All statements other than statements of historical fact contained in this press release are forward-looking statements including, without limitation, all statements related to the intended use of net proceeds from the registered direct offering and the sale of NJ NOLs as well as any expectations of revenues, expenses, cash flows, earnings or losses from operations, cash required to maintain current and planned operations, capital or other financial items; any statements of the plans, strategies and objectives of management for future operations; any plans or expectations with respect to product research, development and commercialization, including regulatory approvals; any other statements of expectations, plans, intentions or beliefs; and any statements of assumptions underlying any of the foregoing. Without limiting the foregoing, the words “plan,” “project,” “forecast,” “outlook,” “intend,” “may,” “will,” “expect,” “likely,” “believe,” “could,” “anticipate,” “estimate,” “continue” or similar expressions or other variations or comparable terminology are intended to identify such forward-looking statements, although some forward-looking statements are expressed differently. Factors that could cause future results to differ materially from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 5, 2020 and in the Company’s other periodic filings with the SEC. The Company’s further development is highly dependent on, among other things, future medical and research developments and market acceptance, which are outside of its control. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this Press Release. Caladrius does not intend, and disclaims any obligation, to update or revise any forward-looking information contained in this Press Release or with respect to the matters described herein, except as required by law.
Contact:
Investors:
Caladrius Biosciences, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: +1-908-842-0084
Email: jmenditto@caladrius.com
Media:
W2O Group
Christiana Pascale
Phone: +1-212-257-6722
Email: cpascale@w2ogroup.com
| Caladrius Biosciences, Inc. | ||||||||
| Selected Financial Data | ||||||||
| (in thousands, except per share data) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2020 | 2019 | |||||||
| (in thousands, except per share data) | (unaudited) | (unaudited) | ||||||
| Statement of Operations Data: | ||||||||
| Research and development | $ | 1,499 | $ | 2,038 | ||||
| General and administrative | 2,558 | 2,554 | ||||||
| Total operating expenses | 4,057 | 4,592 | ||||||
| Operating loss | (4,057 | ) | (4,592 | ) | ||||
| Investment income, net | 71 | 227 | ||||||
| Net loss | (3,986 | ) | (4,365 | ) | ||||
| Less – net income attributable to noncontrolling interests | 4 | 2 | ||||||
| Net loss attributable to Caladrius Biosciences, Inc. common stockholders | $ | (3,990 | ) | $ | (4,367 | ) | ||
| Basic and diluted loss per share attributable to Caladrius Biosciences, Inc. common stockholders | $ | (0.38 | ) | $ | (0.44 | ) | ||
| Weighted average common shares outstanding | 10,623 | 10,027 | ||||||
| March 31, 2020 | December 31, 2019 | |||||||
| (unaudited) | ||||||||
| Balance Sheet Data: | ||||||||
| Cash, cash equivalents and marketable securities | $ | 20,745 | $ | 25,157 | ||||
| Total assets | 22,140 | 27,153 | ||||||
| Total liabilities | 5,156 | 6,600 | ||||||
| Total equity | 16,984 | 20,553 | ||||||
